RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer
Courtney Riedinger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Laura Chambers(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Crystal Tubbs(The Ohio State University Wexner Medical Center), Wafa Khadraoui(University of Miami), Paulina Haight(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Larry J. Copeland(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David A. Mix Barrington(Ochsner Health System), David E. Cohn(The Ohio State University), Floor Backes(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Christa Nagel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 2
Related Papers
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centers
|Gynecologic Oncology|2012|109
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
|Journal of Clinical Oncology|2023|100
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
|Clinical Cancer Research|2023|80
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma
|Gynecologic Oncology|2011|71